Phillip A Thompson

34PUBLICATIONS
156CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersAllergyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Jul 24, 2026
Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.

|Mar 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Alexandre Bazinet, Alessandra Ferrajoli, Nitin Jain

|Mar 17, 2026
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.

Mathias Castonguay, Mary Ann Anderson, Philip A Thompson

|Feb 12, 2026
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Mahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson

|Jan 07, 2026
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Gloria Iacoboni, Emil Ramsø Kyvsgaard, Víctor Navarro Garcés

|Dec 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Sasanka M Handunnetti, Amit Khot, Piers Blombery

Pageof 6

Frequent Collaborators

7 joint publications

Jan Burger

7 joint publications

William Wierda

6 joint publications

Tapan M Kadia

6 joint publications

Prithviraj Bose